ROCKVILLE, Md. and HONG KONG, May 21, 2018 /PRNewswire/ -- Ascentage Pharma, a globalclinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced that interim results from two clinical programs will be presented at the 2018 American Society of Clinical Oncology
The poster sessions of APG-1252, a novel dual inhibitor of Bcl-2/Bcl-xL, and APG-1387, a IAP inhibitor, will be held on June 4.
"We are excited to present initial clinical experience with two of our pipeline candidates," commented Dr. Dajun Yang, Chairman and CEO of Ascentage. "These unique small molecules address complex, protein-protein interactions involved in apoptotic pathways in cancer. We look forward to continuing these single agent studies as well as combination trials with immunotherapy treatments."
ASCO abstracts include:
About Ascentage Pharma
Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. Based on breakthrough technology from the University of Michigan, the Company's expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage has built a rich pipeline of seven clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. For more information, please visit www.ascentagepharma.com.
Media ContactAmy Bonanno E-mail: email@example.com Phone: +1 914 450 0349
Investor ContactChad RubinE-mail: firstname.lastname@example.org Phone: +1 646 378 2947
View original content:http://www.prnewswire.com/news-releases/ascentage-pharma-announces-promising-phase-1-interim-results-in-two-clinical-programs-to-be-presented-at-2018-asco-annual-meeting-300651363.html
SOURCE Ascentage Pharma
Subscribe to our Free Newsletters!